Olivia Vanessa Seraphim

Healthcare Providers

• Rite Aid Corporation and 119 of its affiliates in their prearranged Chapter 11 cases in the U.S. Bankruptcy Court for the District of New Jersey
• Peak Rock Capital in its sale of Paragon Healthcare, Inc., a leading provider of infusion and other specialty pharmacy services, to Elevance Health, Inc.
• Sun Capital Partners-backed Platinum Dermatology Partners in its acquisition of Skin & Cancer Associates, a network of physicians and providers of dermatology services
• Oak Street Health (NYSE: OSH), a primary care company, in its $10.6 billion sale to CVS Health (NYSE: CVS) 
• VSP Vision in its acquisition of Professional Eye Care Associates of America, a community of independent eye care professionals, from Nautic Partners
• One Equity Partners in its strategic investment of InfuCare Rx, a national provider of specialty infusion therapies
• Clayton, Dubilier & Rice in its acquisition of Vera Whole Health, a provider of corporate healthcare services
• TPG Growth in its partnership with Novant Health Enterprises to expand MedQuest Associates, a provider of diagnostic imaging facilities
• TCR, alongside Avryo Health Services, in its investment in 7to7 Dental, a dental service organization
• Knox Lane in its acquisition of All Star Healthcare Solutions, a healthcare staffing firm focused on the locum tenens markets
• Olympus Partners in the sale of Soliant, a provider of workforce solutions in K-12 school districts and healthcare facilities, to The Vistria Group
• HGGC in its investment in Dentive, a dental service organization (DSO) that provides management services to dental practices

Healthcare Technology

• Thoma Bravo in its acquisition of Circle Cardiovascular Imaging, a provider of cardiovascular imaging solutions 
  Abry Partners-backed Millennium Trust Company in its acquisition of Benefit Resource, a provider of FSAs, HRAs, HSAs, commuter plans and COBRA administration services, from CIP Capital
• Thomas H. Lee Partners-backed IMO in its acquisition of Melax Technologies, a provider of natural language processing technology used to extract key information from biomedical textual data
• Waud Capital Partners in the sale of Integrated Practice Solutions, a provider of a practice management and electronic health record software platform, to PracticeTek
• Mercato Partners, as lead investor, in the $33 million Series B funding round in Paytient, a provider of Health Payment Accounts (HPAs)
• Vista Equity Partners in its $70 million growth investment in Jebbit, a provider of a zero-party data platform 
• Thoma Bravo and Madison Dearborn Partners-backed Syntellis in its acquisition of Stratasan, a provider of healthcare market intelligence and data analytics
• Thomas H. Lee Partners, as lead investor, in the $50 million Series C financing of Qventus, a provider of AI-powered software for care operations
• Warburg Pincus-backed Experity, a provider of SaaS software solutions and technology-enabled services for the urgent care industry, in its sale to GTCR
• Vista Equity Partners in its strategic investment in iN2L, a provider of person-centered digital engagement solutions for the senior living market
• Sequoia Capital-backed Implantable Provider Group (IPG), a provider of surgical cost management solutions, in its sale to TPG Growth

Life Sciences

• Eli Lilly and Company (NYSE: LLY) in its $1.4 billion acquisition of POINT Biopharma (NASDAQ: PNT), a radiopharmaceutical company
• Montagu Private Equity in its $700 million acquisition of the Medical Device Components business from Johnson Matthey (LSE: JMAT)
• Waud Capital Partners-backed PharmAlliance in its acquisition of Biobridges, a drug development consulting business, from Soliant Health
• Thoma Bravo-backed Bluesight in its acquisition of Medacist, a provider of drug diversion monitoring
• FFL Partners in its investment in Johnson County Clin-Trials, a clinical research site platform serving pharmaceutical and biotechnology companies and contract research
• Eli Lilly and Company (NYSE: LLY) in its $1.075 billion sale of its BAQSIMI product, a nasally administered glucagon, to Amphastar Pharmaceuticals (NASDAQ: AMPH)
• GTCR-backed Maravai Life Sciences (NASDAQ: MRVI) in its $240 million acquisition of MyChem, a provider of proprietary, ultra-pure nucleotides to customers in the diagnostics, pharma, genomics and research markets
• Vitruvian Partners in its acquisition of a majority stake in KCAS Bioanalytical and Biomarker Services, a contract research organization providing development testing services for the biotech, pharmaceutical, and animal health industries